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ABSTRACT 
In the last twenty years, interferon-α (IFN-α) has gained success as an immunotherapy 
for treating such cancers as hairy cell leukemia, malignant melanoma, and renal cell cancer.  
Our goal was to improve the effectiveness of IFN-α therapy by genetically modified the IFN-
α gene to encode a tumor-targeting peptide fused to a functional IFN-α protein.  To ensure the 
targeting peptide worked, a genetically modified reporter gene encoding a secreted alkaline 
phosphatase (SEAP) gene and different mini-peptides were used to determine distribution and 
targeting ability.  The DNA fragment encoding the most effective peptide was selected to 
modify the IFN-α gene construct for therapeutic trials.  This fusion gene encoded the peptide 
with the amino acid sequence of C-D-G-R-C, and demonstrated a higher localization of the 
genetically modified gene product in the tumor local area.  Tumor volume and animal survival 
was measured over several weeks to compare the anti-tumor effects of the IFN-α to CDGRC-
IFN-α treatments.  Results indicate an increase in therapeutic efficacy due to treatment with 
the CDGRC-IFN-α gene over the wild-type IFN-α gene.  Flow cytometry was performed and 
it was determined that both of the tumor targeted gene products, CDGRC-SEAP and 
CNGRC-SEAP share a high affinity for the receptor, Aminopeptidase N (CD13).  In order to 
determine the mechanism responsible for the enhanced anti-tumor effect by CDGRC-IFN-α 
gene therapy, the T cell infiltration, subsequent CTL activity, and tumor vessel density were 
confirmed through immunostaining.  An increase in number of CD8+ T cells was seen, as well 
as an increase in activity of cytotoxic T cells.  Decreased vessel density in CDGRC-IFN-α 
treated animals suggest that this therapy enhanced anti-angiogenesis.  A high level of non-
specific activity was detected in the CTL assay, suggesting involvement of other immune 
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cells, such as NK cells.  Overall, this study describes the first example of using a genetically 
modified immunostimulatory gene encoding tumor-targeted IFN-α for treating tumors.  This 
novel concept may have the potential for increasing therapeutic efficacy of several current 
cancer treatments. 
 viii
CHAPTER 1: INTRODUCTION 
 
One of the most daunting tasks facing the field of cancer therapy today is finding an 
effective means of transporting therapeutic agents to the site of tumors.  The accomplishment 
of this goal would allow for eradication of specific cancerous cells without damaging the 
healthy tissue of critical organs.  The most attractive method would be attacking the cell 
surface proteins that are altered on cancer cells or in the tumor vasculature, given that cancer 
escapes the immune system through genetic changes in protein expression that occurs on 
those cells.  These proteins could be growth factor receptors (Fairbrother et al., 1998), cell 
adhesion molecules (Fukuda et al., 2000), integrins (Pasqualini et al., 1996), or surface 
markers on endothelial cells.  Targeting DNA or viral vector-containing therapeutic genes to 
areas expressing tumor-specific proteins would allow researchers to localize the delivery of 
their treatments.  Tumor-targeted peptides (with 3-9 amino acids) are an attractive group of 
peptides that can increase survival time (Arap et al., 1998), instill a memory immune response 
(Lode et al., 2000), and limit metastasis with great potential to be used for tumor-targeted 
gene delivery (Hetian et al., 2002).  An obvious advantage of peptides alone over viral or 
liposomal vectors for tumor targeting is that most peptides do not elicit an aggressive immune 
response (Shadidi et al., 2003).  In contrast to antibodies, multiple treatments can be given 
without causing systemic toxicity while increasing efficacy.   
With the recent increase in discoveries of functional peptide:ligand pairs, researchers 
are now able to target to specific organs or tissue types (Brown et al., 2000). A main interest 
for the field of cancer research lies in targeting the tumor vasculature, including tumor 
lymphatics as well as tumor blood vessels (Laakkonen et al., 2002).  The extensive diversity 
of molecules expressed in the vasculature provides numerous potential targets for directing 
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gene vectors to tumors in different organs.  Endothelial cells line blood vessels and serve as 
“gateways” to tumor cells.  They contain surface proteins that function as vascular receptors 
able to transduce growth or angiogenic signals (Pasqualini et al., 2000).  The main advantage 
of targeting to endothelial cells is that they are highly accessible from the blood stream, thus 
simplifying the experimental design.  Several peptides express high affinity for endothelial 
markers, such as RGD-4C for integrins ((Pasqualini et al., 1997)  or NGR for Aminopeptidase 
N/CD13  ((Pasqualini et al., 2000).   
The ultimate goal of tumor targeting focuses on attaching chemotherapeutic drugs 
(Arap et al., 1998), apoptotic molecules (Dharap et al., 2006), or DNA molecules (Sacchi et 
al., 2004) to the peptides so that internalization takes place in the tumor cells.   Even 
combinations of these methods have proved very effective.  In 2002, De Groot et al., 
developed a doxorubicin prodrug conjugated to an integrin binding peptide (de Groot et al., 
2002).  The molecule had two peptide sequences, the first for integrin targeting and other for 
activation of doxorubicin by plasmin cleavage.  Regardless of the conjugate used, the goal is 
tumor regression through accumulation of the product within the tumor environment.       
Although the use of peptides to home molecules to the tumor is not a novel process, 
the use of an IFN-α gene genetically modified to encode the peptide sequence, cysteine – 
aspartic acid – glycine – arginine – cysteine (CDGRC) and IFN-α for treating tumors, is a 
new therapeutic approach.  Since IFN-α is known to inhibit angiogenesis, stimulate an 
immune cell response, and induce apoptosis, it was chosen as a potential therapeutic agent to 
modify.  To have the best effect, the modified gene product needed to be anchored in the 
tumor microenvironment so that it enhanced tumor-specific cell death and induced a tumor-
specific immune response.  Yet, to result in a functional therapy, modifying the IFN-α gene 
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should increase the concentration of IFN-α in the tumor as well as not interfere with the 
biological activity of the modified gene product.  Reporter gene expression levels were 
quantified to determine distribution of the gene products containing tumor-targeted peptides 
both in vitro and in vivo.  The DNA fragment encoding the most effective peptide – CDGRC, 
was incorporated into the IFN-α gene construct for our therapeutic trials.  Tumor volume and 
survival was monitored to determine therapeutic efficacy of the targeted IFN-α treatment 
when compared to non-targeted, wild-type IFN-α treatment.  To establish the mechanism 
responsible for the anti-tumor effects, immunostaining of tumor sections was performed.  We 
analyzed infiltration of T cells in the tumor microenvironment, activity of cytotoxic T cells, 
and angiogenic properties of the therapy.  The objective of this project was to determine 1) the 
localization and expression of a targeted reporter gene product, 2) the therapeutic efficacy of 
targeted IFN-α for squamous cell carcinoma treatment, and 3) the mechanism responsible for 
tumor targeted IFN-mediated anti-tumor effects.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Historical Overview 
Cancer is a common worldwide disease afflicting people from all geographies, races, 
social classes, and ages.  Skin cancer is among the most common types of cancer reported in 
the United States.  Basal and squamous cell carcinoma (SCC) are grouped into the category of 
non-melanomas, which are easier to treat than melanomas.  While basal cell carcinoma 
accounts for almost 80% of all non-melanoma skin cancer, squamous cell carcinoma 
represents another 20% of reported cases with other forms comprising the remaining 1% 
(Kwa et al., 1992).   
Non-melanoma cancers are largely treatable.  Regrettably, ever-changing leisure 
habits involving greater exposure to the sun’s UV rays are resulting in a startling increase in 
the incidence of SCC.   Advances in treating these diseases are needed to meet the increasing 
number of patients.  Current immunotherapy, such as IFN-α protein treatment, needs to be 
improved so that a more effective and less debilitating method is available to patients.   
Interferons are a family of secreted cytokines with important physiological functions 
in anti-viral and anti-tumor defense (Alatrash et al.).  First described in 1957 by Isaacs and 
Lindenmann (Isaacs et al., 1987), they were shown to display anti-tumor activity in animal 
models.  IFNs were initially classified according to their separation on HPLC (high pressure 
liquid chromatograghy) profiles into α, β, and γ types, but it became evident that IFN-α was 
produced principally by leukocytes, IFN-β by fibroblasts and IFN-γ by immune cells. 
Exposure of cells to viruses, double-stranded RNA, polypeptides, or cytokines induces 
expression of IFNs (Pfeffer et al., 1998).  
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In the 1970’s, scientists were interested in the IFN molecule for cancer treatment, but 
lack of purification techniques made research difficult.  In 1980, scientists cloned the gene for 
human interferon into a bacterial chromosome, resulting in an inexpensive method to produce 
large amounts of interferon in a culture dish.  Currently, recombinant IFN-α is produced for 
human use by two pharmaceutical companies. IFN-α2a (Roferon A; Roche Laboratories, 
Nutley, NJ, USA) and IFN-α2b (Intron-A; Schering-Plough, Kenilworth, NJ, USA) have 
similar molecular sequences that differ merely by a single amino acid at position 23 (Weiss, 
1998). The majority of clinical trials have been conducted using Intron-A, or IFN-α2b.  
Unfortunately, protein therapy has significant drawbacks like high cost, strong antibody 
response, and toxicity; whereas, gene therapy produces the proteins in vivo and without the 
immunogenic response that some protein therapy produces. 
In order to overcome the problem of toxicity of IFN-α, targeting the genes or the gene 
products to the tumor vasculature with peptides is a promising area of research.  One key 
technique that contributed to the progress of discovering tumor-targeted peptides is the phage 
display. In the last decade, phage libraries have been widely used to identify peptides that 
bind with high affinity to their tumor-associated proteins.  The majority of the peptides 
generated by this method will bind to functionally important domains of their target proteins 
(Ruoslahti, 2000).  George Smith described the first phage library screening technique in 1985 
(Smith, 1985).  Since then, many improvements have been made to increase yield and 
specificity, as well as to decrease time and cost.  Originally, the phage libraries were carried 
out in vitro; however, in recent years the trend has moved toward in vivo panning to isolate 
ligands that localize to the vasculature of tumor tissue (Kolonin et al., 2001).   
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A more recently developed technique is referred to as BRASIL, or biopanning and 
rapid analysis of selective interactive ligands, where cell suspensions incubated with phage 
are centrifuged through a single step organic phase separation.  This method has proven 
faster, more sensitive, and more specific than common phage selection and sorting methods 
(Giordano et al., 2001).  It may also lead to the future discovery of new cell surface protein 
families resulting in more effective targeting peptides.  Giordano et al. first used BRASIL to 
screen phage displays with random peptide libraries on endothelial cells stimulated by 
vascular endothelial growth factor (VEGF). 
2.2 Squamous Cell Carcinoma Review 
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common 
tumor reported in the United States (Greenlee et al., 2001).  It is the fourth most common 
malignancy among human males (Vokes et al., 1993), with more than 40,000 cases diagnosed 
in the U.S. each year and 500,000 world-wide (Silverberg et al., 1989).  Despite aggressive 
surgery and radiation therapy, the survival rate in patients with head and neck cancer has 
remained relatively unchanged over the past three decades (Le et al., 2003); (Forastiere et al., 
2001).   
The cure rate in patients with advanced SCCHN is less than 30% (Chikamatsu et al., 
1999).  There are no effective treatments for patients with multiple metastatic foci, tumors in 
critical locations, disfiguring lesions, or for preventing the recurrence of the disease (Urosevic 
et al., 2002).  Patients with SCCHN are afflicted with a disease that profoundly affects the 
quality of life and its functions such as breathing, eating, and communicating (Liu et al., 
1995).  Many patients are plagued with recurrence that exacerbates problems or even leads to 
death.  The high rate of local recurrence (60%) (Genden et al., 2003), five-year rate of 
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metastasis (5%) (Rowe et al., 1992), and considerable mortality in advanced cases (50-60%) 
(Dimery et al., 1993) that accompany this type of cancer demand the development of 
therapeutic alternatives. 
 Moreover, squamous cell cancer is considered one of the most severe cases of skin 
cancer due to its ability to metastasize.  Historically, squamous cell carcinoma is among the 
most common cancer of white males (Johnson et al., 1992).  Although the National Cancer 
Institute (NCI) does not collect data on the incidence or mortality of SCC (Cohn, 1998), it is 
known that it plays a role in morbidity and mortality among the elderly (Weinstock, 1997).  
The NCI has also determined the lifetime risk for acquiring SCC to be between 9% and 14% 
in men and between 4% and 9% in females (Miller et al., 1994).  Nevertheless, a sharp rise in 
incidence has been noted in the last 30 years (Gallagher et al., 1990; Gray et al., 1997).  
Interestingly, incidence doubles with each 8- to 10-degree decrease in geographic latitude 
with its highest incidence at the equator (Johnson et al., 1992). 
Patients with SCCHN often lack an immune defense or they have defects in their 
immune response.  The immune system is insufficient in the surveillance and elimination of 
malignant cells (Wanebo et al., 1975); (Boon et al., 1994); (Hadden, 1997).  Therefore, it is 
essential to enhance the immune system in order to reduce tumor recurrence by instilling an 
immune memory response (Myers, 1999).  
The subcutaneous SCCVII – C3H/HeJ murine model was chosen because this 
syngeneic tumor-bearing model controls tumor size, site, and temporal appearance between 
groups, which allows for quantitative evaluation of different treatments.  SCCVII has been 
used previously as a model because of its common characteristics to squamous cell carcinoma 
of the head and neck (SCCHN) (O'Malley et al., 1997). 
 7
2.3  Electroporation Overview  
Electrotransfection is the introduction of plasmid DNA or RNA into the interior of 
cells via electric pulses (Golzio et al., 2002).  It is also referred to as electroinsertion or 
electrotransfer (Andre et al., 2004; Golzio et al., 2004).  Because electrotransfection is a 
physical process, it is able to transfect any cell lines regardless of the morphology, size, 
passage, or cell types.  Use of electrotransfection in mammalian cells was first described in 
1982 by Neumann et al.  They demonstrated thymidine kinase gene expression in mouse 
fibroblasts after electrotransfection of the plasmid DNA (Wong et al., 1982).  Using this 
technique, more than four hundred cell lines have been tested since then, and DNA is 
successfully transfected regardless of the cell lines.  Nevertheless, the efficiency of the 
transfections still varies due to the cellular response to various buffers, electrotransfection 
parameters, and cell lines (Cegovnik et al., 2004). 
Electroporation is referred to as induction of cell membrane permeabilization by 
externally applying electric pulses to the cells. Electroporation delivery (EPD) is the injection 
of DNA into the targeted tissue followed by application of electric pulses to promote uptake 
of the DNA by the cells.  EPD is effective in delivering genes to various tissues including 
accessible tumors (Lee et al., 2003), liver (Suzuki et al., 1998), skin (Zhang et al., 1996), and 
muscle (Mir et al., 1999). 
One mechanism for DNA uptake by electroporation is electrophoresis. Because DNA 
is negatively charged, an electroporation field can induce the migration of negatively charged 
DNA molecules, which in turn accumulate in the cytoplasm from the external membrane 
(Wolf et al., 1994). This model is supported by the fact that addition of DNA after electric 
pulses will not induce any DNA uptake by the cells even though the electropores in the cell 
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membrane are not resealed. However, a recent study using fluorescence-labeled DNA and 
video microscopic images indicates that DNA does not instantly translocate into the 
cytoplasm from the external cell membrane under electric pulses (Golzio et al., 2002). 
Instead, the DNA first forms an aggregate with the cell membrane within a millisecond after 
electroporation.  Then several minutes after the electroporation, it translocates into the 
cytoplasm where it slowly travels into the nucleus.  Gene expression takes place hours after 
the transfection (Golzio et al., 2002). 
2.4 Interferon Function in Immune Response to Cancer 
Interferons (IFNs) are a family of related cytokines that mediate a range of diverse 
functions including antiviral, anti-proliferative, anti-tumor, and immunomodulatory activities 
(Stark et al., 1998).  For example, IFN-α is secreted and binds to nearby cells, which triggers 
a signal cascade that inhibits viral replication in those cells.  Alternatively, IFN-α can increase 
expression of major histocompatibility complex (MHC) class I receptors in cancer cells, 
which increases tumor-antigen presentation to T cells.  In turn, natural killer cells (NK) are 
activated by IFN-α to kill tumor cells and to activate macrophages by production of IFN-γ.  
IFN-α is commonly produced in response to viral infection, but studies have shown its 
importance in cancer inhibition as well (Dinney et al., 1998).   
IFNs bind to cell surface receptors which, after dimerization, initiate a cascade of 
phosphorylation reactions in the Janus Kinase – Signal Transducer and Activator of 
Transcription (JAK–STAT) signaling pathway, eventually activating transcription of IFN-
stimulated genes, known as ISGs (Jonasch et al., 2001).  Interactions between interferon 
molecules and their signaling pathways are largely mediated by the proteins encoded by ISGs, 
the best studied of which include the double-stranded RNA-activated protein kinase (PKR), 
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the 2'-5' oligoadenylate (2-5A) synthetases, and the Mx proteins (Stark et al., 1998).  The 
other well characterized category of ISGs includes the signal transducer and activator of 
transcription (STAT) and IFN regulatory factor (IRF) families of transcription factors, which 
are involved in the regulation of both ISG and IFN gene expression (Darnell et al., 1994; 
Nguyen et al., 1997; Stark et al., 1998).  In the case of IFN-α, relevant anti-tumor effects 
include direct cytotoxic effects, anti-angiogenic effects, and increased expression of MHC 
class I molecules, tumor-specific antigens, or adhesion molecules.  Other anti-tumor effects 
are evident, such as T and NK cells activation and proliferation (Jonasch et al., 2001). 
IFN-α is the first cytokine used in human clinical trials that has been shown to reduce 
tumor load in the patient (Gollob et al., 2000).  It is effective in treating several cancers 
including renal cell carcinoma (RENCA) (Coleman et al., 1998), hairy cell leukemia (Zhang 
et al., 1996), malignant melanoma (Gollob et al., 2000), basal cell carcinoma (Buechner, 
1991), squamous cell carcinoma of the head and neck (Benasso et al., 1993), and multiple 
myelomas (Salesse et al., 1998).   Protein therapy is the current method of choice; however, 
there are toxicity and cost problems associated with the long-term administrations of protein 
therapy (Enzinger et al., 1999; Alatrash et al., 2004).  Recently, intratumoral injection of IFN-
α encoding DNA has suppressed hepatocellular carcinomas, prostate cancer (Ahmed et al., 
1999), and squamous cell carcinoma (Li, et al, 2002) in in vivo murine models. 
2.5 αvβ3 Integrin Targeting 
It is common knowledge that integrins not only mediate invasion and metastasis, but 
recent studies have revealed new ways in which they contribute to enhancing squamous cell 
carcinoma. Increased integrin expression can inhibit differentiation or apoptosis of tumor 
cells, allowing the tumor to grow unchecked.  Also, integrins that are expressed by 
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differentiated cells can stimulate or inhibit the proliferation of neighboring tumor stem cells 
(Janes et al., 2006). 
Integrins are a family of at least 25 heterodimeric, transmembrane, cell surface 
receptors mediating cell adhesion and migration (Tuckwell et al., 1993).  They are composed 
of different α and β subunits with each combination resulting in a distinctive ligand binding 
specificity. Of the 25 known integrins, eight bind to RGD (arg-gly-asp) sequences peptides, 
which serve as the main integrin recognition site in the extracellular matrix proteins (Hynes, 
1992).  One type of integrin – αvβ3, is commonly isolated on platelets, osteoclasts, dendritic 
cells, and endothelium (Weiss et al., 2001).  It is highly expressed in endothelial cells of 
angiogenic vessels and exhibits high affinity for matrix metalloproteinase-2 (Silletti et al., 
2001).  The αvβ3 receptor has a wide range of ligands to which it binds, including, but not 
limited to, fibronectin, vitronectin, osteopontin, and fibrinogen (Eliceiri et al., 1999).  By 
limiting binding to only one integrin type, researchers gain the added benefit of controlling 
the side effects and limiting toxicity when using this molecule in cancer treatment.  These 
properties and the three-dimensional structure of αvβ3 suggest that this molecule is a good 
candidate for peptide targeting.  
Assa-Munt et al. produced a cyclic RGD-4C peptide that showed high affinity for αvβ5 
and αvβ3 integrins after screening with a phage library (Assa-Munt et al., 2001).  Their peptide 
– ACDCRGDCFCG, contains four cysteine residues that produced several isomers of 
disulfide linked cyclic peptides.  All these factors lead to a highly restricted RGD peptide yet 
confer high selectivity for integrin receptors.  The specificity of RGD peptide for αvβ5 and 
αvβ3 integrins and the localized expression of those integrins in endothelial cells make this 
peptide a competitive candidate for targeting DNA vectors to the tumor vasculature.  In fact, 
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this peptide has been integrated as part of adenovirus surface protein and has been heavily 
explored to target the virus into αvβ3 expressing endothelial and tumor cells via the RGD-4C - 
αvβ3 interaction, instead of using the natural coxsackie-adenovirus receptors (CAR) that are 
often lost in highly malignant tumor cells (Yamamoto et al., 2005).   
There is a strong possibility that fusing anti-cancer molecules to tumor-targeted RGD 
peptides will be a potentially useful therapy in the future.  Recently, Curnis et al., showed that 
coupling tumor necrosis factor-α (TNF-α) to αvβ3 ligands improves its anti-angiogenic activity 
(Curnis et al., 2004).  They reported that subnanogram doses are enough to induce anti-tumor 
effects when TNF is fused with RGD-4C and co-administered with chemotherapeutic drugs 
like melphalan.  In this paper, they also reported that this complex can bind to TNF receptors 
and induce cytotoxic death signals.  These synergistic effects confer greater anti-neoplastic 
activity and targeting ability, with less toxicity and smaller required doses, than each method 
alone.  They proposed a mechanism that relates the increased chemotherapeutic drug 
penetration to TNF’s ability to alter endothelial barriers and reduce interstitial tumor pressure 
(van der Veen et al., 2000).  
Several peptide sequences bind integrins expressed on endothelial cells in developing 
blood vessels.  These peptides localize in the tumor vasculature, which has a highly 
angiogenic activity.  There are several classes of integrin receptors that show specificity for 
certain organs.  RGD peptides have many advantages over common techniques used today in 
that they are more stable (Ghandehari et al., 2001), can be incorporated into gene delivery 
vectors (Dmitriev et al., 1998), and may even be useful in cancer imaging because of its 
ability to recognize angiogenic vessels in tumors (Chen et al., 2004).   
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2.6 CD13 Binding 
CNGRC (cys-asn-gly-arg-cys), containing the core peptide NGR, is a novel peptide 
for gene therapy because of its effectiveness in delivering anti-tumor compounds to 
angiogenic blood vessels as an aminopeptidase N (APN) ligand (Pasqualini et al., 2000).  A 
common cyclic NGR peptide, CNGRC, homes much more effectively than linear NGR 
motifs, proving that tertiary structure plays an important role in receptor:ligand binding (Arap 
et al., 1998).  Immunohistochemical analysis shows that several isoforms of aminopeptidase 
N, also known as CD13, are differentially expressed in normal epithelium, tumor-associated 
vessels, and myeloid cells.  Studies show that different CD13 isoforms in other tissues express 
tissue-specific epitopes (Curnis et al., 2002).  However, NGR selectively binds only in tumor 
vessel-related isoforms that are expressed on connective tissue, fibroblasts, or mastocytes in 
the tumor stroma (Dixon et al., 1994).   
CD13 isoforms range from 150 to 240 kDa as mature cell surface protein.  25-30% of 
its molecular weight is composed of carbohydrate moieties. By differential utilization of the 
O-glycosylation sites, at least five isoforms can be formed (O'Connell et al., 1991).   The 
biological activity of CD13 varies depending on its microenvironment.  Normally it is 
activated by angiogenic signals to catalyze the removal of NH2-terminal residues from small 
peptides (Riemann et al., 1999), perhaps for antigen presentation (Hansen et al., 1993), 
cytokine or extracellular matrix degradation (Menrad et al., 1993), cell cycle control 
(Lendeckel et al., 1999), or tumor invasion (Saiki et al., 1993).  
Recent work proves that in vascularized tumors, NGR-TNF-α is 10 to 30 times more 
efficient than TNF-α alone (Curnis et al., 2000).  This efficiency lowers the necessary dose 
for tumor eradication, and thus the toxicity, making this an interesting possibility for future 
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treatment.  The anti-tumor activity of TNF relies on damaging tumor vessels and activating 
the adaptive response rather than directly killing cancer cells (Palladino et al., 1987).  The 
immune response mechanism is crucially important in activating a T-cell-dependent response.    
Curnis et al. produced a functional CNGRCG-TNF molecule by recombinant DNA 
technology, with the glycine added as a spacer between TNF protein and the NGR peptide.  In 
2002, Colombo et al. reported that cyclic CNGRC is more effective at targeting in vivo than 
linear CNGRC, or GNGRC.  This short peptide, only five amino acids, is very attractive for 
use in targeting DNA vectors to tumors.  It is also interesting to know that both the RGD 
peptides and these NGR peptides contain twin amino acid residues of RG, which may prove 
that arginine and glycine are key amino acids for tumor targeting. 
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CHAPTER 3: SELECTING A TUMOR VESSEL-TARGETED PEPTIDE 
 
3.1 Introduction 
Interferon-α (IFN-α) has been shown to inhibit tumor growth by enhancing the anti-
tumor immune response (Hiroishi et al., 2000), preventing angiogenesis in the tumor 
vasculature (von Marschall et al., 2003), and inducing apoptosis of the tumor cells (Thyrell et 
al., 2002).  In order to maximize tumor regression by IFN-α, an increased level of IFN-α 
protein in the tumor is required (Ohashi et al., 2005).  One approach is to use intratumoral 
electroporation to increase expression of IFN-α (Li et al., 2001).  However, some IFN-α will 
leak into the extracellular space then into circulation.   If the protein can be attached to a small 
peptide that exhibits tumor vasculature-targeting ability, the IFN-α protein will be restricted in 
tumors.  To facilitate accumulation in the tumor local area, the peptide CDGRC was used here 
to home the secreted IFN-α to the tumor.  Curnis, Assa-Munt, Pasqualini, and others have 
shown that peptides like RGD-4C (Assa-Munt et al., 2001) and NGR (Pasqualini et al., 1995) 
do bind preferentially to receptors expressed in angiogenic vessels. 
Preliminary studies indicated that the RGD complementary sequence, DGR, increases 
tumor localization of a reporter gene construct over a control construct.  In order to add 
stability to the peptide in vivo, two additional disulfide bond creating cysteine residues were 
added to each end of the peptide (Colombo et al., 2002).  Another reason for localizing the 
gene product into the tumor is that, with more IFN-α accumulating in the tumor, there is less 
available in systemic circulation.  Therefore, less circulating IFN-α results in less toxicity and 
a stronger response.  However, to result in a functional therapy, fusion of an IFN-α gene 
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construct to a targeting peptide such as CDGRC, should increase concentration of IFN-α in 
the tumor as well as not interfere with the biological activity of the targeted gene product. 
Using in vitro and in vivo methods, we will compare the biological activity of several 
fusion genes that encode a secreted alkaline phosphatase (SEAP) reporter gene with either the 
CDGRC, CNGRC, or RGD-4C peptide sequences, and a SEAP gene with no targeting motif, 
known as the wild-type SEAP.  By normalizing and comparing expression levels between 
groups, it is possible to identify any fusion proteins that might potentially inhibit activity of a 
therapeutic gene.  Such comparisons will yield important information for the selection of a 
peptide sequence that does not affect the biological function of the fusion protein. 
3.2 Material and Methods 
3.2.1 Reporter Gene Constructs 
The empty plasmid DNA used in these experiments was the control plasmid DNA 
pcDNA 2.1, purchased from Invitrogen (Invitrogen Corporation, Carlsbad, California, USA). 
Plasmid DNA was constructed for two main goals.  First, a group of SEAP fusion genes 
encoding SEAP and a peptide were created for in vivo and in vitro reporter expression studies.  
These constructs contain a CMV promoter, SEAP coding region, tumor vessel-targeting 
peptide, a stop codon, and a polyadenylation sequence.  Restriction enzyme digestion with 
BH1 allowed for CDGRC-SEAP and BH1/Spe allowed for CNGRC-SEAP coding region to 
be inserted into the plasmid.  Several plasmids were made with different peptides to study the 
ability of each to localize in the tumor vasculature.  The most effective peptides proceeded to 
the second aim, which is therapeutic efficacy of interferon treatment.  The same construct 
models were used in the second aim, except the IFN-α gene was substituted for the SEAP 
gene. 
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Figure 3.1 Plasmid Constructs for Reporter Gene Studies 
Plasmid DNA encoding a secreted alkaline phosphatase enzyme was genetically modified to 
produce the following fusion proteins: A) CDGRC-SEAP, B) CNGRC-SEAP, C) RGD-4C-
SEAP (CNGRCCDCRGDCFC), or D) control-SEAP.  Control plasmid contained the SEAP 
coding region but lacked any DNA encoded targeting peptide.  DNA sequence (upper line in 
box) and corresponding to peptide amino acid sequence (lower line in box) listed above.  
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3.2.2 Plasmid Manufacture 
All plasmids were manufactured with the Qiagen EndoFree plasmid preparation kit 
(QIAGEN Inc., Valencia, CA,USA). Residual salts were removed from plasmids by dialysis 
against sterile water (USP) with a Millipore dialysis tube (Millipore Corp., Bedford, MA, 
USA).  Plasmid DNA was used to transfect cells in vitro and deliver target genes in vivo.   
3.2.3  Generation of SCCVII Tumors in Mice 
SCCVII is a spontaneously arising murine squamous cell carcinoma. We obtained this 
cell line from Dr. Candice Johnson’s laboratory at the University of Pittsburgh (Pittsburgh, 
PA, USA) and maintained the cells in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% fetal bovine serum (FBS; Life Technologies, Rockville, MD, USA). We 
inoculated mice subcutaneously with 2 × 105 SCCVII cells in a 30μL total volume of PBS.  
3.2.4  Administration with SEAP Plasmid DNA via Electroporation 
Intramuscular injection of CNGRC-SEAP, CDGRC-SEAP, or control SEAP DNA, 
followed immediately by electroporation was performed according to protocols described 
previously (Li et al., 2002).  The optimal electroporation parameters, 300 V/cm and 20msec 
pulse duration for 2 pulses, were used for gene injection into muscle (Li et al., 2002).  
3.2.5  Reporter Gene Expression Assay 
The expression levels of reporter genes luciferase and secreted alkaline phosphatase 
(SEAP) were quantitated on a Packard LumiCount luminometer.  20μL of supernatant from 
homogenized tissue or in vitro cell culture plates were added to a 96 well plate, followed by 
addition of the luciferase substrate, luciferin.  Luminous intensity was measured at 540nm in 
the Packard luminometer.  Protein levels were measured in the Packard Spectracount 
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spectrometer.  A Pierce BCA Protein Assay Kit (Pierce, Rockford, Ill, USA) was used and the 
plates were read at 540nm in the Packard spectrophotometer. 
3.2.6  Statistical Analysis 
Expression levels of CDGRC-SEAP, CNGRC-SEAP, DGR-SEAP and control DNA 
were the primary outcomes measured. We used the two-sided Student’s t test to compare 
means of individual treatments.  Results were compared among targeted treatment groups and 
between targeted treatment groups and control group. 
3.3 Results 
 3.3.1 In Vitro Activity of Selected Peptides 
To determine which peptide has the best tumor-homing ability, in vivo tumor-targeting 
activity was determined.  This allowed us to choose the most effective peptides to move to the 
therapeutic study.  The first results obtained from in vitro expression experiments identified 
the DGR motif as most effective when compared to the control, followed by RGD-4C (data 
not shown).  Other effective peptides, such as CDGRC and CNGRC are shown in figure 3.2.  
For reasons to be discussed later, we chose to use CDGRC, with the DGR core motif, as our 
tumor homing peptide for the therapeutic aim of this project. 
3.3.2 In Vivo Targeting Ability of Selected Peptides 
CDGRC again showed high expression, as evident in figure 3.3.  When compared to 
the control, RGD-4C (p=0.004) and CNGRC (p=0.0013) were statistically inhibited, while 
CDGRC showed no statistical difference to the control (p=0.179).  This indicates that the 
biological activity of CDGRC-SEAP was not decreased when the peptide was added to the 
SEAP gene.  This data also allowed us to create an index to relate the ratio of the reporter 
gene expression in the tumor to vital organs like the spleen, liver, and lungs. (figure 3.4)  
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Taken together, the in vitro and in vivo data show that RGD-4C and CNGRC inhibit SEAP 
activity, whereas CDGRC does not have this inhibitory effect.  This led us to choose CDGRC 
as the proper tumor-targeting peptide.  This in vivo experiment also proved that the peptides 
do, in fact target their agents to tumors over other organs. 
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Figure 3.2  Biological Activity of wild-type-SEAP vs. Targeted-SEAP genes in vitro 
SEAP activity compared between treatment with 2μg DNA of either non-targeted, wild-type-
SEAP (control-SEAP) or tumor-targeted-SEAP fusion constructs transfected in 1x106 
SCCVII cancer cells (n=3).  Tumor-targeted SEAP fusion genes encode CDGRC-SEAP or 
CNGRC-SEAP.  A total of 10μg luciferase DNA was added before splitting cells to normalize 
the relative expression levels in vitro. Cells incubated overnight for SEAP and luciferase 
activity assays. (Index = SEAP activity / Luciferase Activity)      
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Figure 3.3  Reporter Gene Product Localization in vivo 
SEAP activity compared between wild-type-SEAP (control-SEAP) and tumor-targeted-SEAP 
fusion constructs in C3H mice (n=5).  Tumor-targeted-SEAP fusion genes encode CDGRC-
SEAP or CNGRC-SEAP.  Groups treated once, ten days after tumor inoculation, by 
intramuscular administration via electroporation (IM-EP) of 20μg plasmid DNA in 30μL 
saline.  Tumors and organs collected five days after treatment.  Activity compared between 
SCCVII tumor samples (tumor) and pool of lung, liver, and spleen tissue (organ).   
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Figure 3.4 Index of Tumor to Tissue Reporter Gene Expression in vivo 
SEAP activity compared between wild-type-SEAP (control-SEAP) and tumor-targeted-SEAP 
constructs.  Tumor-targeted-SEAP fusion genes encode CDGRC-SEAP or CNGRC-SEAP.  
Activity levels normalized to control for simple comparison (control-SEAP index = 1.0).  
Expression compared between tumor samples and pool of lung, liver, and spleen.  See figure 
3.3 for treatment schedule. 
 
 
 
 3.4 Discussion 
Both the in vivo and in vitro experiments identified the key peptides for targeting the 
tumor vasculature without affecting the biological function of the fusion protein.  Ultimately, 
the CDGRC sequence was chosen because of its high expression, increased localization, and 
optimal number of amino acids in the peptide.  Some problems have been reported using viral 
vectors coated with RGD-4C.  Because its relatively large length of nine amino acids, a bulky 
structure is created which leads to steric hindrance at the binding site (Mok et al., 2005).  The 
smaller peptide, DGR is effective by itself, but addition of the cysteine residues to the 
terminal ends of the peptide provides more stability for the gene product. The ideal peptide is 
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small enough not only to evade an immunogenic response, but more importantly to maintain 
the biological activity of its modified gene product.   
The in vivo data surprisingly shows the control-SEAP with the highest expression.  
With respect to the lower expression of targeted-SEAP, this inhibition could be due to the 
peptide modification.  If so, the positive results of this experiment suggest that of all targeted 
constructs, the CDGRC-SEAP is the least affected by its peptide.  Since there is no statistical 
difference between the control-SEAP and the CDGRC-SEAP, this means the inhibition is not 
significant; yet the difference between CDGRC-SEAP and CNGRC-SEAP prove that our 
CDGRC is the most effective peptide for targeting tumors.  Another finding, evident from 
figure 3.3, illustrates the ability of these peptides to increase localization in the tumors over 
other organs in the body.  Perhaps the SEAP product has a natural tumor homing ability; 
however, it is unknown as to why the control-SEAP construct appears to localize in the tumor 
as well.  . 
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CHAPTER 4: BINDING ACTIVITY OF TUMOR-TARGETED  
CDGRC-SEAP 
 
4.1 Introduction 
 
Several key peptides have been discovered that home to their cognate receptors in the 
tumor vasculature.  One is the NGR peptide which binds a membrane metalloprotease known 
as aminopeptidase N, or CD13 (Curnis et al., 2002).  Studies show that several isoforms of 
CD13, are differentially expressed in normal epithelium, tumor-associated vessels, and 
myeloid cells (Curnis et al., 2002).  They report that CD13 isoforms in a variety of other 
tissues express tissue-specific epitopes.  However, NGR selectively binds only in tumor 
vessel-related isoforms that may be expressed on connective tissue, fibroblasts, or mastocytes 
in the tumor stroma (Dixon et al., 1994).  Since DGR differs from NGR by only one amino 
acid, it is structurally very closely related to NGR.  Therefore, it was of interest to study 
whether the CDGRC-SEAP could bind to CD13 with similar affinity as CNGRC-SEAP.    
The best choice, according to the literature, would have been to genetically create a 
CNGRC-SEAP construct for testing; however, in our preliminary studies, CNGRC-SEAP 
yielded lower activity than the control-SEAP.  This suggests that CNGRC-IFN-α may not be 
as effective as a therapeutic agent.  Obviously, to maintain the same biological activity as 
non-targeted IFN-α, a different peptide is needed for genetic modification of the therapeutic 
gene.  Our preliminary results indicate that CDGRC would serve as the best targeting peptide 
to obtain our goals. 
Another reason for choosing CDGRC was based on the structural similarity between 
asparagine (N) and aspartic acid (D).  These two amino acids differ by only one side group, as 
seen in figure 4.1.  As a result, we were also interested in testing whether or not CDGRC-
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SEAP would have similar activity as CNGRC-SEAP.  Fortuitously, the CDGRC peptide 
shares some complementary similarity to RGD-4C, which binds αvβ3, an integrin receptor also 
found on endothelial cells.  These binding alternatives may lead to an increase in effectiveness 
of this therapeutic agent and peptide combination. 
 
       
Figure 4.1 Similarities in Structure between the Amino Acids, Asn (N) and Asp (D) 
The similarity in structure may explain the related results obtained when comparing CDGRC 
to CNGRC 
 
 
 
As mentioned previously, neither the in vivo nor the in vitro biological activity was 
inhibited by modifying the SEAP gene construct with CDGRC.  This gives CDGRC the 
potential to anchor in the tumor vasculature and function naturally as an immune modulator.  
Since we were interested in finding a targeting peptide that does not inhibit biological activity 
yet binds specifically in the tumor vasculature, we examined the ability of CDGRC and 
CNGRC modified SEAP reporter genes to bind to endothelial cells expressing CD13 in 
relation to a wild-type SEAP control.   For these reasons, we chose to analyze the CDGRC 
and CNGRC binding activity to CD13 expressing cells using flow cytometry to determine the 
amount of shift in cell counts between the groups.   
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4.2 Material and Methods 
 4.2.1 Tissue Culture 
 Tissue cultures of 5H36 murine endothelial cells were prepared and grown in DMEM 
(Dulbecco's modified Eagle's medium) with 10% (v/v) FBS (fetal bovine serum).  The cells 
were grown at 37 °C in a 5% CO2, 95% air incubator.  C3H mice were injected with CDGRC-
SEAP, CNGRC-SEAP, or control-SEAP in the tibialis muscle.  Five days later, the tissue was 
collected, homogenized, and the protein extracted.  SEAP protein expression levels were 
tested to ensure presence of specific SEAP protein.  Endothelial cells were incubated with 
control-SEAP, CDGRC-SEAP, or CNGRC-SEAP protein, then stained with anti-CD13-FITC, 
and analyzed by FACScan. 
4.2.2 Flow Cytometric Analysis 
Endothelial cells were grown in DMEM (Dulbecco’s Modified Eagle Medium) with 
10% FBS.  Cells were suspended in RPMI medium and then split into three separate 1.5μL 
microcentrifuge tubes at a concentration of 1x106 cells per 50μL.  Cells were incubated with 
CDGRC-SEAP, CNGRC-SEAP, or control-SEAP for 30 minutes at room temperature.  Then, 
incubated with fluorescein isothiocyanate (FITC) anti-CD13 antibody for 30 minutes at room 
temperature.  Cells were washed with 3mL of PBS, the supernatant was decanted, and the 
residual fluid and cells were vortexed.  1% formaldehyde-PBS was immediately added to fix 
the cells for analysis on a FACScan machine. 
4.3 Results 
 4.3.1  CDGRC Binds Endothelial Cells 
 In order to determine the binding affinity of CDGRC for cognate receptors like CD13, 
a modified flow cytometry procedure was performed.  An endothelial cell line expressing 
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CD13 was used to test for binding affinity due to its presence in blood vessels.  SEAP, 
CDGRC-SEAP, or CNGRC-SEAP was added to an endothelial cell suspension.  After 
incubation, anti-CD13-FITC was added to each group.  The results show a backwards shift in 
cell staining by anti-CD13-FITC between the control and the two targeted-SEAP groups.  
This suggests that both CNGRC and CDGRC bind to CD13 to compete with the anti-CD13-
FITC antibody for receptor binding.  Although the two targeted groups exhibit a marked shift 
from the control, the CDGRC shift is slightly more meaningful.  Suggesting that CDGRC is a 
very effective ligand for targeting molecules to the CD13 receptor.  
 
 
Figure 4.2 Targeted CDGRC-SEAP and CNGRC-SEAP Inhibit Anti-CD13 Staining 
Endothelial cells incubated with CDGRC-SEAP, CNGRC-SEAP, or control IgG protein.  
Cells were stained by FACS and the noticeable backward shift is illustrated. 
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4.4 Discussion 
The current peptide targeting studies have spurned many peptides that can be targeted 
to specific tissue in the body.  Many share common amino acids in their sequences.  For 
example, the glycine – arginine (G-R) sequence is evident in peptides like RGD-4C, 
CNGRC, and others (Arap et al., 1998).  Building upon that knowledge, we chose to test the 
effectiveness of CDGRC.  Both structural similarities and preliminary studies indicated the 
potential of CDGRC as an effective targeting motif.  Flow cytometry data correlates with 
other studies to indicate that CDGRC is, in fact, a functional and effective peptide.  Flow 
cytometric analysis shows that CNGRC and CDGRC can bind CD13 and inhibit anti-CD13 
antibody from binding. 
  Recently, integrins have been a main topic of interest in the development of tumor 
targeting peptides (Pasqualini et al., 1997)).  Currently, RGD-4C is a popular motif for 
combining with chemotherapy drugs or gene therapy.  DGR also shares a high similarity with 
RGD-4C core, which is known to bind to the integrin, αvβ3.  Thus, we examined the binding 
of DGR to the αvβ3 crystal structure.  The crystal structure of the extracellular portion of αvβ3 
reveals the binding pocket in great detail (Xiong et al., 2001).  By analyzing the crystal 
structure of the peptide and its receptor, the affinity of peptides that bind the active site can be 
formulated.  Binding of DGR to the αvβ3 integrin receptor was reported to be higher than the 
binding of the integrin to RGD-4C.  Perhaps, this CDGRC motif serves as a double-edged 
sword that can target both the CD13 receptor and the αvβ3 integrin.  The key “GR” motif 
found in many vessel targeting peptides appears to play a significant role in binding its 
receptor. 
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CHAPTER 5: THERAPEUTIC EFFICACY OF TUMOR VESSEL-TARGETED 
CDGRC-IFN-α 
 
5.1 Introduction 
Within the last decade, therapeutic use of IFN-α to treat certain cancers has become 
more common (Kluin-Nelemans et al., 1998); (Miller et al., 2000).  Many of these cancers are 
marked by abnormalities in the cell-mediated immune response that either cause injury to the 
host, lack sufficient ability for tumor clearance, or both (Byrnes et al., 2001).  Unfortunately, 
therapeutic efficacy of IFN-α protein therapy is considered limited due to the restraints of cost 
and acquired immunity against repeat administrations (Macey et al., 1997; Kefford, 2003).  
By targeting the drug of choice to a specific tissue, such as a tumor, anchoring the therapeutic 
agent at the site of the tumor may increase efficacy. 
According to Curnis et al., recombinant TNF-α chemically conjugated to CNGRC 
resulted in a 12-15 fold increase in tumor regression over wild-type TNF-α in lymphoma and 
melanoma models.  Interestingly, they report no significant difference in toxicity between the 
two treatment groups (Curnis et al., 2000).  Nevertheless, a 12-fold increase in efficacy would 
allow for a decrease in dose required to achieve the same effect.  Therefore, in practice, the 
toxicity would be lowered by peptide targeting treatments.  By lowering the necessary dose, 
the toxicity, which is encountered with current IFN-α therapy, will be reduced (Macey et al., 
1997). 
To target IFN-α into tumors, our approach begins with a genetically modified version 
of the IFN-α gene encoding an extra five amino acid tumor vessel-targeting sequence.  Using 
this targeting motif, we expect to find accumulation of the gene product in the tumor local 
area.  We hypothesize that anchoring IFN-α in the tumor allows for an increased exposure to 
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immune cells which, in turn, leads to a stronger immune response against the malignant tumor 
cells.  To test this hypothesis, we chose to compare the therapeutic efficacy between the gene 
construct encoding CDGRC-IFN-α with a non-targeted, wild-type IFN-α gene.   
5.2 Materials and Methods 
5.2.1 IFN-α and CDGRC-IFN-α Gene Constructs 
The following gene constructs were used for therapeutic studies.  Each construct 
contains a CMV promoter, SEAP coding region, tumor vessel-targeting peptide, a stop codon, 
and a polyadenylation sequence.  The DNA sequence encoding for the targeting peptide was 
TGT AAT GGT CGT TGT (CDGRC).  
   
 
 
 
 
 
 
 
Figure 5.1 Plasmid Constructs for Therapeutic Studies 
Plasmid DNA encoding non-targeted, wild-type IFN-α was used as a positive control.  
The same plasmid was modified to contain a gene encoding for a CDGRC-IFN-α 
fusion protein.   A non-coding plasmid was used as another control.  This non-sense 
plasmid encoded for an unrelated, non-functional protein.  
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5.2.2 Generation of SCCVII Tumors in Mice and Monitoring Tumor Growth 
SCCVII/SF is a spontaneously arising murine squamous cell carcinoma. We obtained 
this cell line from Dr. Candice Johnson’s laboratory at the University of Pittsburgh 
(Pittsburgh, PA) and maintained the cells in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% fetal bovine serum (FBS; Life Technologies, Rockville, MD). We inoculated 
mice subcutaneously with 2 × 105 SCCVII cells in a 30μL volume.  When the established 
tumors reached a measurable size (4–6 mm) in diameter, the animals were randomly divided 
into groups of five mice each for efficacy experiments.  Five mice were used for vessel 
density and T-cell infiltration studies, and five mice for gene expression experiments.  After 
initiation of IFN-α DNA treatment, we monitored tumor growth every 3 days.  We measured 
tumor diameters with a digital caliper and calculated the tumor volume with the formula: 
V=π/8(a × b2), where V is the tumor volume, a is the maximum tumor diameter, and b is the 
diameter at 90 ° to a (Puisieux et al., 1998).  At the completion of each experiment, the mice 
were euthanized by CO2 narcosis. 
5.2.3 Treatment with IFN-α Plasmid DNA via Electroporation 
Intratumoral injection of IFN-α, CDGRC-IFN-α, or non-coding, control plasmid 
DNA, followed immediately by electroporation was performed according to protocols 
described previously (Li et al., 2002).  The optimal electroporation parameters, 450 V/cm and 
20msec pulse duration for 2 pulses, were used for gene injection into tumors (Li et al., 2002).  
5.2.4  Statistical Analysis 
The Kaplan-Meier estimator in the Statistica Software Package was used to generate 
survival curves for the animals treated with wild-type IFN-α, CDGRC-IFN-α, and control 
DNA for each of two experiments.  A comparison of the survival experience between the two 
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treatment groups was made with Gehan Wilcoxon test, separately for both experiments, as 
well as with a one way ANOVA and Kruskal-Wallace test to analyze by non-parametric 
statistics. The data were then combined, and Kaplan-Meier curves were generated for the two 
treatment groups (5 animals in each group).  p values less than 0.05 were considered 
statistically significant. 
5.3 Results 
 5.3.1 Tumor Targeted CDGRC-IFN-α Inhibits Tumor Growth in C3H mice 
 It has been reported previously that gene therapy with IFN-α causes regression of 
tumors (Li et al., 2002).  To improve efficacy of this treatment, tumor-targeted IFN-α therapy 
was investigated.  We discovered that genetically modifying the gene to encode for IFN-α and 
CDGRC, improved the anti-tumor response in SCCVII bearing C3H mice.  Two independent 
studies were performed and similar results were obtained in both.  Two treatments were 
administered 10 days apart, and tumor volume and survival in days were recorded until the 
tumors exceeded 2000mm3, or the mice died naturally.  Compared to the control groups both 
IFN-α and CDGRC-IFN-α significantly inhibited tumor growth (p value of 0.014 and 0.026).  
Furthermore, the CDGRC-IFN-α group showed a significant enhancement of inhibition over 
the wild-type IFN-α treatment (p value of 0.05 and 0.046) 
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Figure 5.2 Tumor Growth Inhibition by CDGRC-IFN-α 
SCCVII-bearing C3H mice were treated by intratumoral administration via electroporation 
with 20μg of CDGRC-IFN-α, wild-type IFN-α, or control (non-coding) DNA in 30μL of 
saline (n=9).  Treatments were administered twice, 10 days apart.  Treatment dates are noted 
(arrow) in above figure.  Tumor volume was measured every 3 days until tumors exceeded 
2000mm3 or mice died of complications.   
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Figure 5.3 Tumor Growth Inhibition by CDGRC-IFN-α 
SCCVII-bearing C3H mice were treated by intratumoral administration via electroporation 
with 20μg of CDGRC-IFN-α, wild-type IFN-α, or control (non-coding) DNA in 30μL of 
saline (n=9).  Treatments were administered twice, 10 days apart.  Treatment dates are noted 
(arrow) in above figure.  Tumor volume was measured every 3 days until tumors exceeded 
2000mm3 or mice died of complications.    
 
 
  
5.3.2 Tumor Targeted CDGRC-IFN-α Increases Survival of C3H Mice 
In addition to measuring tumor volume, a survival curve was generated using the 
computer software, Statistica 7.  Again, the two IFN-α treated groups showed a longer 
survival than the control group.  In agreement with the tumor volume measurements, 
CDGRC-IFN-α prolonged the lifespan over wild-type IFN-α.  According to the Gehan-
Wilcoxon test, there was a statistical significance between IFN-α and CDGRC-IFN-α.  In 
addition, one-way ANOVA analysis and the non-parametric Kruskal-Wallace test also 
showed a statistical significance.  Significance was found when comparing IFN-α to CDGRC-
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IFN-α and when comparing the two IFN-α treated groups to control (p value IFN-α = 0.027; p 
value CDGRC-IFN-α = 0.003).   
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Figure 5.4 Survival Time Increased by CDGRC-IFN-α 
SCCVII-bearing C3H mice were treated by intratumoral administration via electroporation 
with 20μg of CDGRC-IFN-α, wild-type IFN-α, or control (non-coding) DNA in 30μL of 
saline (n=9).  Tumor volume was measured and survival was monitored until tumors 
exceeded 2000 mm3 or mice died naturally.  Survival plotted on Statistica 7 software package.  
Treatments administered on days 10 and 20 after tumor inoculation. 
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5.4 Discussion  
 It is notable that treatment with CDGRC-IFN-α resulted in a significant inhibition of 
tumor growth and a prolonged life expectancy for SCCVII tumor-bearing mice.  Tumor-
targeted IFN-α was compared to wild-type IFN-α under the assumption that the protein would 
accumulate in the tumor local area, thus enhancing the anti-tumor response.  Our results 
indicate that electroporation delivery of CDGRC-IFN-α led to a greater therapeutic efficacy 
than treatment with wild-type IFN-α.  It is worth mentioning that in the first study, all of the 
mice from the control group either died or were euthanized extremely early in the trial due to 
the aggressive nature of the tumors.  Remarkably, a nearly two-fold difference in tumor 
volume was detected in both treatment groups and both studies at day 30.  The second 
experiment was terminated after 3 weeks, while the original study continued until all mice 
succumbed to the tumor.   
One interesting observation was made in respect to visible necrosis of the tumors.  
Since no data was collected on necrosis of the tumors, it is merely anecdotal.  However, tumor 
volume data may be misleading due to the fact that volume is determined by the outer 
diameter of the tumor, not “true volume”.  CDGRC-IFN-α treatment resulted in obvious 
necrosis of every tumor in the group.  Even though wild-type IFN-α did inhibit tumor growth, 
the amount of visible necrosis was not as evident as in the CDGRC-IFN-α group.   
 Previous studies had reported tumor eradication by IFN-α treatment (Li et al., 2002).  
No tumors were eradicated in this study, but CDGRC-IFN-α substantially limited the tumor 
growth and induced a more effective anti-tumor immune response than non-targeted IFN-α.  
Perhaps the stage of the tumors was more advanced, and thus, more difficult to completely 
eradicate.  There was one case of near eradication in the CDGRC-IFN-α group, but none in 
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the wild-type group.  This evidence strongly suggests that CDGRC-IFN-α has an improved 
therapeutic efficacy over the non-targeted wild-type IFN-α. 
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CHAPTER 6: ENHANCED ANTI-TUMOR RESPONSE MECHANISM MEDIATED 
BY TUMOR-TARGETED IFN-α  
 
6.1 Introduction 
IFN-α provides a basis for the mechanism of a cellular immune response by inducing 
the expression of tumor-related antigens and MHC class I molecules.  When given 
intratumorally, IFN-α also results in local and systemic T cell and NK cell activation 
(Mitropoulos, 2005).  The mechanism for the anti-tumor effects of IFN-α can be attributed to 
its role of stimulating the cellular immune response.  Although, it has been shown that IFN-α 
has anti-viral, anti-proliferative, and apoptosis inducing effects, the focus of this project deals 
with the immunomodulatory effects (Stark et al., 1998).  T cell infiltration, anti-angiogenesis, 
and cytotoxic T lymphocyte (CTL) activity are the key players in tumor inhibition and 
regression. 
Our hypothesis was that accumulation of IFN-α in the tumor will lead to an increase in 
activation of immune cells.  Most importantly, triggering NK cells and dendritic cells to 
attack cancer cells and stimulate T cells to proliferate, respectively.  This combination leads to 
the observed anti-tumor effects, including cancer cell death and anti-angiogenesis in the tumor 
vasculature.  In order to determine whether CD8+ T cells were responsible for this anti-tumor 
effect, tumor infiltration of CD8+ T cells was analyzed.  In addition, the CTL activity from 
each group was measured.  To determine if accumulation increased IFN-α inhibition, tumor 
vessel density was examined.  These results led to our understanding of the anti-tumor effects 
mediated by tumor-targeted IFN-α treatment.  
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6.2 Materials and Methods 
6.2.1 Immunostaining Analysis 
We performed immunostaining to determine vessel density and T-cell infiltration. The 
vessels in the tumor tissues were stained using an antibody to CD31, an endothelial cell 
marker (1 : 200; BD Biosciences; Los Angeles, CA), and the infiltrated CD8+ T cells were 
stained with an anti-CD8+ antibody (1 : 50 BD Bioscience) as previously described in detail 
(Li et al., 2001). The number of vessels and the CD8+ T cells were scored from a minimum of 
four microscopic fields from five independent tumors treated with IFN-α, CDGRC-IFN-α, or 
control DNA plasmid injected by electroporation as described previously. The average 
number of vessels per field was determined under a microscope at ×40 magnification, and the 
average number of CD8+ T cells per field was determined under a light microscope at ×20 
magnification. 
6.2.2 Fluorescent Microscope-Based CTL Activity Assay 
Cytotoxic T lymphocyte (CTL) activity was evaluated using a CyToxiLux kit 
(OncoImmunin, Inc., Gaithersburg, MD), a single cell-based fluorogenic cytotoxicity assay 
(Liu et al., 2002). Splenocytes were obtained 15 days after the treatment from SCCVII tumor-
bearing C3H mice. The effector cells from splenocytes were primed by co-culture with 
mitomycin C-treated SCCVII tumor cells in a ratio of 25:1 for 3 days, in RPMI-1640 medium 
with 20% FCS. Effector cells were incubated with red fluorescence-labeled target SCCVII 
cells and AT-84 cells, to analyze non-specific activity, in a ratio of 100:1, 50:1, and 25:1 in a 
volume of 200μl overnight, and then incubated with the quenched-green fluorescence-labeled 
caspase substrate for 1 hour. The apoptotic target cells (red/yellow color cells) were examined 
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using an Olympus BX41 fluorescence microscope (Olympus, Japan). CTL activity was 
calculated using the equation:  
% specific killing = apoptotic target cells – spontaneous apoptotic target cells   x  (100)   
     total target cells 
 
6.2.3 Statistical Analysis 
The number of vessels and CD8+ T cells were counted, and the specific cytotoxic 
activity of CTLs was measured using a fluorescent microscope-based CTL assay.  We used 
the two-sided Student’s t test to compare means of individual treatments when the primary 
outcome was statistically significant.  Results were compared between targeted treatment 
groups and between targeted treatment groups and control group. 
6.3 Results 
 6.3.1 CD8+ Infiltration Increased by CDGRC-IFN-α 
 IFN-α has been shown to affect tumor growth by three main mechanisms:  
1) inhibition of angiogenesis, 2) activation of apoptosis, and 3) enhancement of the immune 
response.  In this project, two of these mechanisms were investigated.  First, the cellular 
immune response was explored by analyzing CD8+ T cell infiltration and CTL activity.  
Immunostaining with anti-CD8+ antibody detected a statistically significant increase in CD8+ 
T cell infiltration between the CDGRC-IFN-α and IFN-α groups (p=0.002).   Two 
independent experiments were performed and similar results were obtained in each.  
Interestingly, in both experiments there was no significance between the IFN-α and control 
groups (p=0.293 and 0.179), but the targeted IFN-α treatment did increase T cell infiltration.  
Data from the two experiments were combined and illustrated as figure 6.1. 
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Figure 6.1 CD8+ T Cell Infiltration Increased by CDGRC-IFN-α 
SCCVII-bearing C3H mice were treated by intratumoral administration via electroporation 
with 20μg of CDGRC-IFN-α, wild-type IFN-α, or control (non-coding) DNA in 30μL of 
saline (n=9).  One treatment administered ten days after inoculation of tumor cells.  Ten days 
post-treatment, tumors were collected, sectioned, and immunostained with anti-CD8+ 
antibody for T cell infiltration counting. 
 
 
 
6.3.2 CTL Activity Increased by CDGRC-IFN-α 
We hypothesize that tumor-restricted accumulation of IFNα is more effective in 
inducing a tumor-specific anti-tumor immune response.  To test this, we assayed the CTL 
activity using splenocytes from different treatment groups.  This assay measures the percent 
of cytotoxic activity by the primed splenocytes.  Again, the CDGRC-IFN-α performed the 
best out of all treatment groups.  The anti-tumor response of the targeted treatment with the 
concentration of effector to target cells at 100:1 was significantly better at killing tumor cells 
than either the wild-type IFN-α (p=0.00027) or the control (p=0.0028).  This assay also 
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showed a difference in anti-tumor effects between IFN-α and the control group in terms of 
CTL activity (p=0.0008). 
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Figure 6.2 Cytotoxic T Lymphocyte Activity Increased by CDGRC-IFN-α 
SCCVII-bearing C3H mice were treated by intratumoral administration via electroporation 
with 20μg of CDGRC-IFN-α, wild-type IFN-α, or control (non-coding) DNA in 30μL of 
saline (n=5). Activation of tumor specific cytotoxic T lymphocytes determined by percent 
killing activity of SCCVII tumor cells by primed splenocytes.  Two treatments were 
administered ten days apart.  Five days after the second treatment, spleens were removed and 
splenocytes (effector cells) co-cultured with specific SCCVII cells (target cells) and non-
specific AT-84 cells (control cells). 
 
 
 
6.3.3 CD31+ Vessel Density Decreased by CDGRC-IFN-α 
After determining that the cellular immune response was enhanced by IFN-α 
treatment, we next examined the anti-angiogenic property of CDGRC-IFN-α vs. IFN-α.  To 
determine if CDGRC-IFN-α inhibits angiogenesis, immunostaining with anti-CD31 antibody 
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was performed to identify tumor vessels in tumor sections.  Two independent experiments 
were carried out and similar results were obtained.  In the first trial, when compared with the 
control group, both IFN-α (p=0.027) and targeted IFN-α (p=0.0002) treatment was effective 
at reducing vessel growth.  A difference between IFN-α treatment groups was also seen 
(p=0.0013).  In the second trial, there was again significance between the two IFN-α treatment 
groups compared to the control (p=0.0218 and p=0.0278) and to each other (p=0.048).  Data 
from the two experiments were combined to produce figure 6.4. 
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Figure 6.3 Tumor Angiogenesis Inhibited by CDGRC-IFN-α 
SCCVII-bearing C3H mice were treated by intratumoral administration via electroporation 
with 20μg of CDGRC-IFN-α, wild-type IFN-α, or control (non-coding) DNA in 30μL of 
saline (n=9).   One treatment administered ten days after inoculation of tumor cells.  Ten days 
post-treatment, tumors were collected, sectioned, and immunostained with anti-CD31 
antibody for vessel density counting. 
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6.4 Discussion  
 Although T cells represent a large arm of the immune response against tumors, it is 
evident that IFN-α does not directly activate or stimulate T cells.  However, the accumulation 
of IFN-α in the tumor environment does cause increased activation of other effector cells like 
NK cells, which in turn produce cytokines that activate T cells.  Non-specific activity 
accounted for about half of the cytotoxic response according to the results from the non-
specific AT-84 data (figure 6.3).  On the other hand, both the SCCVII and AT-84 cell lines 
were derived from C3H mice, so they may share enough genetic similarities that the primed T 
cell response against SCCVII cells will recognize either type. 
 These invading T cells are also responsible, at least in part, to reducing the tumor 
vessel load.  CTL activity results are evidence for the anti-angiogenic role of cytotoxic T 
lymphocytes in IFN-α treated individuals.  In order to determine the amount of tumor specific 
CTL activity, another oral cancer cell line was used as target cells in the CTL Assay.  AT-84 
cells were used to determine if the tumor cytotoxicity was specific to SCCVII-primed T 
lymphocytes, or if other non-specific immune cells, like NK cells, were responsible.  We 
found that the activity in the AT-84 was also relatively high.  This is the result not of CTLs, 
but more likely of NK cell stimulation and its activation of macrophage and T cells.  By 
comparing activity at three different concentrations of effector:target cells, an overall view of 
CTL activity can be seen.    
 The anti-angiogenic property of IFN-α was evident, although not as pronounced in the 
repeat experiment.  It is clear that IFN-α does contribute to the reduction of vessel density 
when it is targeted to the vessels themselves.  This is evident in the significant difference 
between the CDGRC-IFN-α treated and control treated animals in both experiments (see 
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figure 6.4 and 6.5).  Previously, we reported that CDGRC-SEAP could bind to CD13 
receptors commonly found on endothelial cells.  If the CDGRC-IFN-α fusion protein is 
binding to endothelial cells of tumor vessels, then it might be accumulating in the tumor 
vasculature.  This would explain why the CDGRC-IFN-α treatment was more effective at 
eliciting an anti-angiogenic response than a non-targeted IFN-α treatment. 
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CHAPTER 7: SUMMARY AND CONCLUSIONS 
 The main purpose of this project was to determine if anchoring therapeutic gene 
products in the tumor microenvironment, so that they accumulate within the tumor, would 
increase therapeutic efficacy and improve the anti-tumor response.  Current therapies use 
recombinant IFN-α protein, but some trials have reported toxicity after multiple, high doses.  
Our approach is to modify and inject the IFN-α DNA to produce the targeted protein in vivo 
to overcome this toxicity.  
For this project, IFN-α was used as the therapeutic agent due to its anti-angiogenic, 
immune cell stimulating, and apoptosis enhancing properties.  We analyzed the vessel density 
and T cell infiltration by immunostaining to determine the anti-angiogenic and immune 
stimulating properties, respectively.  One important finding was that CDGRC-IFN-α inhibited 
angiogenesis.  This was observed by a decrease in vessel density counts when endothelial 
cells comprising the tumor vessels were immunostained by anti-CD31 antibodies.  We also 
found that there was an increase in CD8+ T cells in the tumors, when sections were stained 
with anti-CD8+ antibodies. 
The peptide, CDGRC, was chosen because it is small enough to be non-immunogenic, 
it did not inhibit the expression of a reporter gene product in vivo or in vitro, and it binds to 
CD13, and potentially αvβ3, to anchor in tumor vessels.  Both in vitro and in vivo experiments 
showed that CDGRC could localize its agent to tumors.  In addition, there was no affect on 
biological activity of the modified gene.   
Finally, this study is important to the field of gene therapy as well as cancer biology 
because of several reasons.  The identification of this targeting peptide can be applied not 
only to therapeutic anti-cancer agents, but also to reporter genes, radionucleotides, or other 
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imaging molecules for various experiments in vitro or in vivo.  Second, this research shows 
that by anchoring and accumulating IFN-α in the tumors by the CDGRC motif, the 
therapeutic efficacy was increased.  This increase leads to a decrease in tumor volume and an 
increase in survival time, both of which indicate an effective therapy.     
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